This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechnology: Archive
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market?
by Zacks Equity Research
KROS advances rinvatercept for Duchenne muscular dystrophy, with a phase II trial planned for 2026 after gaining FDA orphan drug designation.
SRPTPositive Net Change PTCTNegative Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Roche Advances Obesity Pipeline as Petrelintide Meets Phase II Goal
by Zacks Equity Research
RHHBY says the ZUPREME-1 study meets its goal as petrelintide delivers up to 10.7% weight loss with placebo-like tolerability, supporting further advancement.
RHHBYPositive Net Change NVONegative Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
QURE Stock Crashes 32% in a Week: Here's What You Should Know
by Zacks Equity Research
uniQure stock plunges 32% in a week after the FDA says AMT-130 phase I/II Huntington's disease data are not sufficient as primary evidence for a potential marketing application.
CPRXNegative Net Change USNANegative Net Change QUREPositive Net Change ALXOPositive Net Change
biotechnology biotechs medical pharmaceuticals
After Golden Cross, Iron Mountain (IRM)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
IRMNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
TNGX Stock Hits Record High on Inking Collaboration Deal With ERAS
by Zacks Equity Research
Tango Therapeutics stock hits a record high after signing a clinical collaboration with Erasca to test the ERAS-0015/vopimetostat combo in MTAP-deleted RAS-mutant cancers.
CPRXNegative Net Change USNANegative Net Change ERASNegative Net Change TNGXPositive Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Best Health & Fitness Stocks to Buy Now for Strong Growth
by Nilanjan Choudhury
GRMN, HLF and AMWL stand out in a booming wellness market as wearables, nutrition products and telehealth platforms reshape how consumers pursue healthier lives.
AMZNNegative Net Change AAPLNegative Net Change GRMNPositive Net Change HLFNegative Net Change AMWLNegative Net Change
biotechnology biotechs healthcare medical-devices thematic
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline?
by Zacks Equity Research
Reblozyl tops $2.3B in annualized sales, emerging as a key drug for Bristol Myers as demand rises in MDS-related anemia and new study data support expansion.
BMYNegative Net Change GERNPositive Net Change KROSNegative Net Change
biotechnology biotechs medical pharmaceuticals
Bayer Advances Roundup Settlement With Missouri Court Approval
by Zacks Equity Research
BAYRY wins preliminary court approval for a proposed Roundup class settlement, a key step in managing long-running glyphosate litigation and future liabilities.
BAYRYNegative Net Change CPRXNegative Net Change ANIPNegative Net Change REPLPositive Net Change
biotechnology biotechs medical pharmaceuticals
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
by Debanjana Dey
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead? Let's see.
GHNegative Net Change BIAFPositive Net Change
biotechnology biotechs genetics medical medical-devices
Gaming and Leisure Properties (GLPI) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
GLPINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines